Drug Trial Radar · NCT03546907
Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of SAR440340 (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)
Last checked: Nov 19, 2026Latest source record: Nov 22, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
343
Actual
Start
Jul 16, 2018
Primary completion
Oct 3, 2019
Study completion Feb 21, 2020
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- Collaborators
- Regeneron Pharmaceuticals
- First posted
- Jun 6, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 40 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Primary Objective: To investigate effects of SAR440340 (anti-interleukin-33 \[IL-33\] monoclonal antibody \[mAb\]) compared with placebo, on the annualized rate of moderate-to-severe acute exacerbations of COPD (AECOPD) over up to 52 weeks of treatment. * Moderate exacerbations were recorded by the Investigator and defined as AECOPD that require either systemic corticosteroids (such as intramuscular, intravenous or oral) and/or antibiotics. * Severe exacerbations were recorded by the Investigator and defined as AECOPD requiring hospitalization, emergency medical care visit or resulting in death. Secondary Objectives: To investigate effects of SAR440340 compared with placebo, on improving respiratory function, as assessed by pre-bronchodilator forced exploratory volume in 1 second (FEV1). To evaluate effects of SAR440340 compared with placebo, on post-bronchodilator FEV1. To evaluate effects of SAR440340 compared with placebo, on duration from baseline to first moderate or severe AECOPD event. To evaluate effects of SAR440340 compared with placebo, on safety and tolerability.
Conditions
- Chronic Obstructive Pulmonary Disease
Interventions
SAR440340Drug
Pharmaceutical form: Solution for injection; Route of administration: SC
PlaceboDrug
Pharmaceutical form: Solution for injection; Route of administration: SC
Any Inhaled Corticosteroids as prescribed by treating physician as standard of careDrug
Pharmaceutical form: Aerosol or Dry Powder inhaler Route of administration: Inhaled
Any Long Acting Beta Agonist as prescribed by treating physician as standard of careDrug
Pharmaceutical form: Aerosol or Dry Powder inhaler; Route of administration: Inhaled
Any Long Acting Muscarinic Agonist as prescribed by treating physician as standard of careDrug
Pharmaceutical form: Aerosol or Dry Powder inhaler; Route of administration: Inhaled
Any short-acting β agonist as prescribed by treating physician as standard of careDrug
Pharmaceutical form: Aerosol or Dry Powder inhaler; Route of administration: inhaled
Primary outcomes
What the sponsor says the trial is designed to measure.
- Annualized Rate of Moderate to Severe Acute Exacerbation Events in Chronic Obstructive Pulmonary Disease (AECOPD) ParticipantsTime frame: From Baseline up to Week 52
Locations
83 sites in 10 countries. Site status is shown where the registry gives one.
Investigational Site Number 8400002
Los Angeles, California
Investigational Site Number 8400003
Riverside, California
Investigational Site Number 8400006
Rolling Hills Estates, California
Investigational Site Number 8400015
Westminster, California
Investigational Site Number 8400013
Jacksonville, Florida
Investigational Site Number 8400012
Columbia, Maryland
Investigational Site Number 8400016
North Dartmouth, Massachusetts
Investigational Site Number 8400020
South Dartmouth, Massachusetts
Investigational Site Number 8400011
Minneapolis, Minnesota
Investigational Site Number 8400005
Jamaica, New York
Investigational Site Number 8400019
Chapel Hill, North Carolina
Investigational Site Number 8400004
Raleigh, North Carolina
Investigational Site Number 8400001
Medford, Oregon
Investigational Site Number 8400009
Philadelphia, Pennsylvania
Investigational Site Number 8400007
Plano, Texas
Investigational Site Number 8400008
Greenfield, Wisconsin
Investigational Site Number 0320001
Buenos Aires, Argentina
Investigational Site Number 0320005
Caba, Argentina
Investigational Site Number 0320002
Caba, Argentina
Investigational Site Number 0320004
Caba, Argentina
Investigational Site Number 0320006
Quilmes, Argentina
Investigational Site Number 0320003
Rosario, Argentina
Investigational Site Number 0360005
Bedford Park, Australia
Investigational Site Number 0360002
Chermside, Australia
Investigational Site Number 0360004
Clayton, Australia
Investigational Site Number 0360003
Frankston, Australia
Investigational Site Number 0360006
Kent Town, Australia
Investigational Site Number 0360001
Murdoch, Australia
Investigational Site Number 1240002
Burlington, Canada
Investigational Site Number 1240009
Hamilton, Canada
Investigational Site Number 1240003
Montreal, Canada
Investigational Site Number 1240001
Montreal, Canada
Investigational Site Number 1240005
Québec, Canada
Investigational Site Number 1240006
Saint-Charles-Borromée, Canada
Investigational Site Number 1240008
Trois-Rivières, Canada
Investigational Site Number 1240007
Vancouver, Canada
Investigational Site Number 1240004
Victoriaville, Canada
Investigational Site Number 1520002
Quillota, Chile
Investigational Site Number 1520001
Santiago, Chile
Investigational Site Number 1520007
Santiago, Chile
Showing 40 of 83 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.